SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 15, 2026

ORKA

Oruka Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $239K total
Actionable Insight • Neutral

No material signal from this insider cluster given the negligible dollar amount relative to market cap. Monitor for upcoming catalysts (e.g., clinical data, pipeline updates) that could drive the stock, but this filing alone does not warrant a trading action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$83.04
T+0 close · Jul 15, 2026 · via day close
Latest settled
−1.12%
T+60 · $82.11
Vs SPY
−4.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $83.04entry
  2. T+1 · 4mo ago +11.63%α +12.62% · $92.70
  3. T+5 · 4mo ago +10.73%α +12.40% · $91.95
  4. T+20 · 3mo ago +30.20%α +26.58% · $108.12
  5. T+60 · 6w ago −1.12%α −4.83% · $82.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders (CMO and SVP Finance) sold shares totaling ~$1.45M, but this represents only 0.027% of the $5.3B market cap, making it a routine and immaterial event. The sales appear tied to option exercises and are not indicative of a bearish view.

Key Financial Metrics

Direction
selling
Total Value
$1.5M
Insiders
2

Key Facts

  • CMO Joana Goncalves sold ~$604K in open-market sales on July 15, 2026, following option exercises.
  • SVP Finance Arjun Agarwal sold ~$846K in open-market sales on July 13, 2026, following option exercises.
  • Total open-market sales of ~$1.45M represent 0.027% of ORKA's $5.3B market cap.
  • All sales were preceded by derivative exercises (cash and non-cash), consistent with routine tax or diversification planning.

Financial Impact

Total insider sales of ~$1.45M are trivial relative to $5.3B market cap (0.027%).

dilution

Risk Factors

  • Insider sales could increase if the stock continues to appreciate, but current volume is immaterial.
  • Lack of C-suite (CEO/CFO) participation reduces informational content of the cluster.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ORKA-1784160084727

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026